Introduction
Patients with coronary, cerebral or peripheral arterial disease frequently receive antiplatelet therapy (APT). Depending on the individual risk profile, one (mono-APT), two (dual-APT) or even three platelet inhibitors are administered to reduce the risk of arterial thrombosis [1] [2] [3] [4] [5] .
Perioperative management of elective patients with a low risk of arterial thrombosis who receive aspirin only has been established by the POISE-2 trial [6] , which demonstrated that aspirin can safely be paused perioperatively. The POISE-2 trial, however, excluded patients after recent stent implantation, who have a particularly high risk of developing coronary thrombosis, if antiplatelet therapy is prematurely stopped [7, 8] . This risk further increases during the acute phase after surgery [9] .
The Guidelines of the European Society of Cardiology and the American College of Cardiology/American Heart Association therefore suggest proceeding with urgent noncardiac surgery without stopping APT in patients after recent stent implantation if the bleeding risk is acceptable, or stopping the P2Y12-receptor antagonist if the bleeding risk outweighs the risk of coronary thrombosis [1, 10] . However, antiplatelet therapy increases the perioperative bleeding risk [11] . Continuing APT might therefore not be feasible for procedures such as neurosurgery, where prevention of bleeding is essential. Management of patients on APT with a moderate to high risk of coronary thrombosis throughout urgent procedures bearing a high risk of surgery-related bleeding therefore requires reduction of the bleeding risk during surgery, ideally without increasing the risk of coronary thrombosis.
In vitro studies show that addition of fresh platelets improves the function of aspirin-inhibited platelets and to a lesser extent of clopidogrel or prasugrel-inhibited platelets [12] . We proposed to transfuse two platelet concentrates (PCs) preoperatively to manage patients on APT who require urgent interventions with a high bleeding risk [13] . Preoperative platelet transfusions allow maintaining APT until 12 to 24 h before surgery and restart of antiplatelet therapy as soon as 6 h after surgery to avoid coronary thrombosis. This management allowed major surgical interventions without major bleeding complications in 14 patients on antiplatelet therapy in a pilot study [13] . Furthermore, we observed no cardiovascular thrombosis in 72 patients with intracranial bleeding who required neurosurgery using our management [14] . However, both studies were too small to adequately assess the risk of new cardiovascular thrombosis induced by platelet transfusions.
Here, we report the safety outcomes of 181 consecutive patients on APT who received preoperative platelet transfusions and early restart of APT to facilitate urgent noncardiac surgery.
Materials and methods

Patients, data assessment and ethics
This observational, retrospective cohort study was performed as quality assessment of transfusion management. The protocol of pre-interventional platelet transfusion is the standard protocol for perioperative management of patients on APT requiring an urgent intervention with increased bleeding risk at our institution. The final decision on whether the intervention is associated with an increased bleeding risk was made by the surgeon.
Consecutive patients being transfused with two PCs before non-cardiac surgery were identified by the blood bank information system for the years 2012 to 2014. Their medical records were assessed for antiplatelet medication (aspirin, clopidogrel, prasugrel or ticagrelor), any postoperative arterial or venous thrombotic complications, bleeding in the area of surgery after wound closure, bleeding requiring re-intervention, red cell transfusions, comorbidities (coronary artery disease, congestive heart failure, hypertension, diabetes, peripheral artery disease, renal impairment and cardiac stents) and the type of surgery performed. All records of patients with a documented cardiac event were re-evaluated by a cardiologist (AH). Follow-up was until discharge or postoperative day 30. Patients discharged before postoperative day 30 were reassessed for any readmission due to thrombotic or bleeding complications until day 30.
Patients not receiving antiplatelet drugs and patients with intracranial bleeding as the primary indication for surgery were excluded from the analysis. The ethics committee of the University Medicine of Greifswald approved the study.
Objectives
The primary objective was to determine the incidence of cardiac adverse events, including myocardial infarction, acute heart failure and postoperative cardiac troponine T (cTnT) increase.
Secondary objectives were the incidences of ischemic stroke, peripheral arterial thrombosis, venous thrombosis, bleeding complications, number of red cell transfusions and mortality.
Definitions and risk stratification
Myocardial infarction, acute heart failure, ischemic stroke, and arterial or venous thrombosis were classified according to standard definitions [2, [15] [16] [17] . Cardiac work-up was driven by the clinical decision of the treating physicians in the case of suspected cardiac disease.
Bleeding complications were classified using POISE-2-criteria [18] and stratified as surgery related (if they developed at surgical wounds) or not related to surgery (if they developed at other locations).
The risk of major cardio-and cerebrovascular events (MACCE) was determined for each patient as proposed by the working group on perioperative hemostasis of the ISTH [19] . This comprised the parameters: time period between the last arterial event and surgery, the history of previous stent thrombosis, type of inserted stent (drug eluting or bare metal stent), myocardial infarction, stroke, CHADS 2 score, and antiplatelet therapy for primary prophylaxis. Acute morbidity was prospectively determined in every patient at hospital admission using the American Society of Anesthesiologists (ASA) score [20] .
Statistical analyses
Safety endpoints were determined as proportions with 95% confidence intervals (CIs) [21] . Risk factors for cardiac adverse events, bleeding at the site of surgery and transfusion of red cell concentrates were identified by multivariable logistic regression analysis. Each variable (platelets< 150 Gpt/l, aspirin monotherapy, clopidogrel monotherapy, dual APT, intake of non-steroidal antiinflammatory drugs, catecholamine therapy, peripheral artery disease, congestive heart failure, arterial hypertension, diabetes, atrial fibrillation, renal failure, high MACCE risk, ASA >3, neurosurgery, general surgery, orthopedic surgery, and urology, otolaryngology and gynecology surgery) was assessed in a univariate model in a first step and adjusted for age and sex in a second step. Finally, a full model was created including age, sex and the risk factors identified in step 2 where the 95% CI did not include the value of 1. Risk factors were considered relevant if the respective 95% CIs of each odds ratio obtained by the full model did not include the value of 1, were large enough to be considered clinically relevant (i.e. with odds ratios around 5 or larger) and retained their relevance in the multivariable models. Analyses were performed with SPSS, version 22 (IBM, Ehningen, Germany). All estimates obtained by the univariate, the ageand sex-adjusted, and the combined model analyses are summarized in the supplemental Tables S1-3.
Results
Patients and interventions
The main characteristics of patients and invasive interventions are given in Table 1 . In total, 181 patients (63 female) were identified who received two preoperative PC transfusions to reverse the effect of antiplatelet drugs. Median platelet counts of the patients before surgery were 237 9 10 9 L À1 . Four patients had preoperative platelet counts < 100 9 10 9 L À1 .
In total, 404 PCs were transfused before and after surgery during the observational period. Patients received a median of two PCs (range, 2-8). PCs contained a mean amount of 2.5 9 10 11 platelets based on our internal quality control measurements. This corresponds to a total preoperative dose of~5 9 10 11 platelets. Additional PCs were transfused in 13 (7.2%) patients to treat intraoperative bleeding, as recommended by our protocol. No acute transfusion reaction related to platelet transfusion occurred.
Before surgery, 72 patients (39.8%) received dual antiplatelet therapy, 21 (11.6%) clopidogrel alone, and 88 (48.6%) aspirin alone. Among aspirin-only patients, three took a combination of aspirin and dipyridamole. Antiplatelet therapy had been restarted within 24 hours after surgery in 89 (49.2%) patients (64 aspirin, 6 clopidogrel and 19 dual APT), and within 72 h in 120 (66.3%) patients (75 aspirin, 7 clopidogrel and 38 dual).
The risk of MACCE was high in 63 patients (34.4%), moderate in 103 (56.9%) and low in 15 (8.3%) patients. Sixty-seven (37.0%) patients had cardiac stents and 128 (70.7%) had pre-described coronary artery disease. Further comorbidities were congestive heart failure (30 patients, 16.6%), hypertension (151 patients, 83.4%), diabetes (67 patients, 37.0%), peripheral artery disease (30 patients, 16.6%) and renal impairment (43 patients, 23.8%).
Surgical procedures included: 69 neurosurgical interventions (10 cranial, 59 spine interventions); 64 general surgical procedures (eight thoracic surgeries, 42 abdominal surgeries, seven vascular surgeries, seven hematoma evacuations); 25 orthopedic interventions (18 osteosyntheses including the upper and lower extremities and spine, four hip-joint replacements, two lower limb amputations, one hematoma evacuation); 14 urologic interventions (seven transurethral bladder resections, four nephrectomies, three renal punctures and invasive catheter insertions); six otolaryngological surgeries; and three gynecological surgeries (one hysterectomy, two mastectomies). Median time until discharge was 13 days after surgery.
Cardiac adverse events
No acute coronary thrombosis occurred. However, 10 patients (5.5%; 95% CI, 3.0-9.9%) developed a cardiac adverse event ( Table 2 , Table S4 ), of whom four had documented congestive heart failure before surgery. Three patients (1.7%; 95% CI, 0.6-4.8%) developed an acute coronary syndrome (two non-ST-segment-elevation myocardial infarctions and one ST-segment-elevation myocardial infarction). Four patients developed acute heart failure (2.2%; 95% CI, 0.9-5.5%) and three patients (1.7%; 95% CI, 0.6-4.8%) developed a postoperative increase of cTnT levels without further clinical symptoms. In three patients (two with myocardial infarction), coronary thrombosis was excluded by percutaneous coronary angiography (Table S4 ).
In the remaining patients, cardiac symptoms were judged to be caused by a combination of heart failure, critical illness and circulatory distress after surgery. Coronary occlusions were clinically considered to be so unlikely that coronary angiography was not indicated. Table S1 ).
Ischemic strokes, and peripheral arterial and venous thrombosis
One ischemic stroke (0.6%; 95% CI, 0.1-3.1%; postoperative day 9), two peripheral arterial occlusions (1.1%, 95% CI, 0.3-3.9%; postoperative days 1 and 24) and two
Bleeding and red cell transfusions
Postoperative bleeding occurred in 30 patients (16.6%; 95% CI, 11.9-22.7%), of whom 22 had bleedings that were surgery related (12.2%; 95% CI, 8.2-17.7%; Table 3 , Fig. 1) . Seventeen of the surgery-related bleedings (9.4%; 95% CI, 6.0-14.5%) were major or life-threatening bleedings according to POISE-2-criteria (including one fatal surgical bleeding, not caused by platelet dysfunction) and 12 required re-intervention (6.6%; 95% CI, 3.8-11.2%). In 10 of the patients with surgery-related bleeding, antiplatelet treatment had already been restarted when bleeding occurred. Surgery-related bleedings occurred between the day of surgery and postoperative day 13. Importantly, four patients with postoperative bleeding additionally developed a cardiac adverse event during their further clinical course (one non-ST-segment elevation myocardial infarction, two cardiac failures (one patient died), and one cTnT elevation).
Urologic surgery (OR, 5.3; 95% CI, 1.5-18.5) was associated with an increased risk of surgery-related bleeding (Fig. 1, Table S2 ). Bleedings not related to surgery occurred in eight patients (4.4%; 95% CI, 2.5-8.5%; three urinary tract, three gastrointestinal, one thoracic and one endotracheal bleed).
Fifty-nine patients (32.6%; 95% CI, 26.2-39.7%) received red cell transfusions throughout the perioperative course. Red cell transfusions were associated with high ASA scores > 3 (OR, 2.4; 95% CI, 1.1-5.4) and the use of vasopressors (OR, 4.5; 95% CI, 1.3-16.0; Table S3 ).
Mortality
Five patients died during the follow-up period (2.8%; 95% CI, 0.01-6.3%). Causes of death were sepsis (two patients), respiratory arrest (one patient), heart failure (one patient) and massive re-bleeding (one patient). 
Discussion
This study is the first systematic assessment of preoperative platelet transfusions as a rescue strategy to transiently reverse APT before urgent and semi-urgent non-cardiac surgery. We analyzed patients at high risk of coronary thrombosis, who also had a high risk of surgery-related bleeding. Of the 181 enrolled patients, over 90% had at least a moderate risk of MACCE, over 40% received dual APT at admission and~40% had cardiac stents. Patients receiving preoperative platelet transfusions did not develop coronary thrombosis (type 1 myocardial infarction) or in-stent thrombosis (type 4b myocardial infarction) [16] in our study, conferring a 95% CI of 0-2.1%. However, we observed 10 (5.5%) non-thrombotic cardiac adverse events during the follow-up period. Eight of these patients developed the cardiac event during postsurgical intensive care treatment. This observation in critically ill patients may result from preexisting heart failure before non-cardiac surgery [16] and may reflect perioperative coronary supply/demand mismatches, rather than coronary vessel thrombosis. Consistently, a high risk of MACCE was associated with an increased risk of cardiac adverse events in our study.
Three non-occlusive symptomatic myocardial infarctions occurred, corresponding to an incidence of 1.7% (95% CI of 0.6-4.8%). A large analysis involving 9 566 277 hospitalizations in the USA found that~1% of 
Bleeding risk related to the type of surgery
Neurosurgery n = 69
General n = 64
Orthopedic n = 25
Urology n = 14
Otolaryngology n = 6
Gynecology n = 3 0% (95% CI 0-56.2%) Fig. 1 . Risk of surgery-related bleeding and 95% confidence interval, stratified by the type of surgery.
© 2018 International Society on Thrombosis and Haemostasis patients develop perioperative myocardial infarctions throughout non-cardiac surgery [22] . In this study, less than 18% had coronary artery disease and less than 4% had prior percutaneous coronary interventions. In comparison, our cohort involved patients with a much higher risk of myocardial infarction. Two-thirds had pre-described coronary artery disease and over one-third had cardiac stents. This may explain the slightly higher incidence of myocardial infarction observed in our cohort. The VISION study found that increased postoperative cTnT levels were associated with 30-day mortality in patients undergoing non-cardiac surgery [23] , indicating the relevance of perioperative cardiac adverse events. As we did not systematically assess cTnT levels before and after transfusion, we cannot judge whether platelet transfusions are associated with changes in cTnT levels. Surgery-related bleeding occurred in over 12% of patients. Two-thirds of those patients experienced a major or life-threatening bleeding, and more than half of the bleedings required surgical re-intervention. The one fatal bleeding, however, was related to surgical complications after pulmonary lobectomy and unlikely to be the result of impaired platelet function. However, nearly half of the patients who developed surgery-related bleeding had already restarted antiplatelet therapy, a fact that may have contributed to these bleedings. This highlights the importance of defining the optimal time-point to restart antiplatelet agents in order to prevent bleeding after surgery. We found urologic surgery to be a risk factor for bleeding, which may be caused by increased fibrinolysis in the urogenital tract [24] .
Only a few studies assessed the perioperative bleeding risk in patients with APT undergoing non-cardiac surgery [25] . The prospective POISE-2 trial reported an overall bleeding rate of 4.6% in nearly 5000 patients left on aspirin throughout elective non-cardiac surgery [6] . However, the POISE-2 trial excluded patients after recent coronary stent insertion on dual APT. The risk of re-bleeding was 9.5% in a prospective study by Albaladejo et al. in 1134 patients with coronary stents under mono or dual APT who underwent non-cardiac surgery [26] . However, in this study, fewer patients received an urgent intervention and a higher proportion underwent less invasive endoscopy than in our study, which limits comparisons. Estimations of to what extent platelet transfusions reduce the risk of bleeding cannot be made based on our single-arm study. This requires a sufficiently powered randomized controlled trial and the present study provides the safety data on coronary thrombosis as a basis for such a trial.
One-third of patients required red cell transfusions, mainly patients with high preoperative ASA scores, patients undergoing orthopedic surgery and/or those receiving vasopressors. This suggests that acute and severe illness may have triggered red cell transfusions in these patients rather than bleeding due to APT.
The strength of our study is that consecutive patients on APT were enrolled who required surgery with an increased risk of bleeding. Furthermore, all patients received the same standard dose of two PCs before surgery. It is unlikely that we missed any patients because all transfusions are well documented in our electronic blood bank system. A further strength is that we included highrisk patients like those who received recent drug-eluting stent implantation and patients undergoing neurosurgery. Our study is limited by its retrospective design. Further cardiac work-up was only driven by clinical suspicion of ACS; therefore, under-reporting of subclinical events, such as cTnT elevation, cannot be excluded. However, stent or coronary vessel thrombosis would result in severe cardiac symptoms, making under-reporting of this objective very unlikely. Moreover, we had a relatively high proportion of neurosurgical patients in our cohort. This reflects the inclusion criterion that the intervention must be a high bleeding risk intervention. We do not believe that this caused a bias of the primary objective. If platelet transfusions triggered thrombotic cardiac adverse events, this would also occur in neurosurgical (especially in stented) patients.
If preoperative platelet transfusions are considered in patients under APT, it is mandatory to take the half-lives of antiplatelet drugs and their metabolites into account, because they would also inhibit transfused platelets. Aspirin has a short half-live of 15-20 min [27] . The active metabolite of clopidogrel has a half-life of 30 minutes [28] , but can circulate for up to 6-8 h after intake because of considerable variation in absorption and metabolism [29] . The active metabolite of prasugrel has a half-life of 8 hours [30] . About 3-4 half-lives of antiplatelet drugs or their metabolites are necessary for their clearance. Therefore, surgery should be postponed whenever possible for 12-24 h after the last intake of aspirin, clopidogrel or prasugrel. Importantly, the described protocol is not feasible for reducing the risk of bleeding in patients receiving ticagrelor. Ticagrelor is a reversible P2Y12 receptor inhibitor. Due to the high plasma levels of ticagrelor at therapeutic concentrations, its active derivatives are present in the blood for up to 96 h after its last intake [31] . These metabolites also inhibit transfused platelets. Finally, the thrombin receptor antagonist vorapaxar is present in plasma for 126-269 h [32] .
Although potential adverse effects associated with blood transfusion have been discussed for a long time, the safety of platelet transfusion has been even more debated since the PATCH study, which found a worse outcome of transfused non-surgical patients with intracerebral bleeds complicating APT [33] . Our transfusion approach was designed to improve hemostasis before non-cardiac surgery in order to prevent bleeding and not to treat bleeding itself without an indication for surgery. Therefore, data from the PATCH trial cannot directly be transferred to our patient population and clinical scenario. In addition, platelet transfusions were found to be independent risk factors for venous thrombosis in medical and surgical intensive care patients [34] . In our cohort, 1% of patients developed a venous thrombosis. This proportion is far too small for conclusions. However, both studies highlight the potential of platelet transfusions to cause unwanted effects, which will need to be addressed in future studies.
Of note, nearly 30% of patients may be resistant to clopidogrel treatment [35, 36] . The proportion of clopidogrel-resistant patients was not assessed in our study. These patients may not have the same perceived benefit from platelet transfusions regarding improvement in hemostasis, compared with those without clopidogrel resistance. Platelet function testing may be able to select these patients before surgery [37] , if available and practicable in emergencies.
In conclusion, we found no evidence that platelet transfusions before non-cardiac surgery in patients on APT cause coronary in-stent thrombosis. However, non-thrombotic cardiac adverse events and recurrent bleedings occur in this setting. Whether prophylactic platelet transfusions improve the outcome of these patients in comparison to other management strategies needs to be investigated in a randomized controlled trial. Our data provide the basis for designing such a trial. Meanwhile, we suggest that our management strategy is a feasible strategy in patients on APT, in order to allow urgent surgery with a high risk of bleeding. 
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